Healthcare Data Monetization Market worth $1.3 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets forecasts the global healthcare data monetization market will grow from $0.7 billion in 2026 to $1.3 billion by 2031, a 14.5% CAGR, driven by EHR adoption, cloud infrastructure, AI analytics and demand for linked real-world datasets. The market is shifting from standalone data licensing toward data-as-a-service, analytics subscriptions and AI-ready data platforms; examples include Regeneron's potential $200 million TriNetX investment and Datavant's minority investment by KKR and Neuberger. North America led the market in 2025, supported by digital-health infrastructure, interoperability regulation and major cloud and healthcare IT vendors.

Analysis

This is not a read-through to hyperscalers: healthcare-data revenue remains immaterial to GOOG, MSFT, ORCL and CRM, while implementation spend is likely competed away by large integrators. The investable scarcity is privacy-preserving linkage and longitudinal real-world-data access, where IQV and private Datavant can convert pharma demand into recurring, higher-switching-cost revenue. IQV's upside is less raw data licensing than attaching analytics, trial design and commercial workflow services to its installed life-sciences relationships; that can support mix-led margin expansion over the next 6-18 months.

REGN and TMO are more credible second-order beneficiaries than generic software vendors. Better-linked clinical and omics data can reduce patient-identification and evidence-generation bottlenecks, increasing R&D capital efficiency rather than creating material standalone data revenue; the impact would emerge over multiple development cycles, not in the next quarter. Conversely, data aggregators face rising customer concentration and a structural risk that pharma internalizes datasets or negotiates lower take rates as interoperable standards improve.

Near term, this press release is insufficient to alter estimates: it is vendor-sponsored TAM work, and the purported market definition appears too narrow to map cleanly onto public-company segment disclosures. The tradable catalyst is evidence of booked recurring data-platform revenue and expansion in life-science RPO/CRO demand during the next 1-3 earnings cycles, particularly at IQV and TMO. Falsification would be IQV reporting flat-to-down technology/analytics bookings, weaker biopharma R&D budgets, or new US privacy enforcement that raises consent, linkage, and compliance costs faster than pricing can recover.

Contrarian view: interoperability commoditizes cloud storage and generic analytics, concentrating economics in provenance, patient identity resolution, proprietary clinical networks, and regulatory-grade audit trails. That favors specialized platforms over SNOW or DOMO; however, public markets already value much of the AI-healthcare optionality, so avoid treating a mid-teens TAM forecast as a near-term revenue catalyst.

Key Decisions for Investors

• Maintain/establish a 6-12 month overweight in IQV versus ACN: use a modest pair position, long IQV/short ACN, to isolate recurring life-sciences data and workflow exposure from commoditized services. Target 10-15% relative upside if platform bookings accelerate; exit if IQV's next two quarters show no improvement in technology-enabled revenue or biopharma demand.
• Add TMO on 6-18 month weakness rather than chase the data theme: its differentiated opportunity is attaching linked real-world data to clinical-research workflows. Require evidence that PPD utilization and biopharma order trends are stabilizing; downside is continued biotech funding pressure and CRO pricing competition.
• Do not initiate longs in GOOG, MSFT, ORCL, SNOW, or DOMO solely on this development. Set an alert for disclosed healthcare-cloud bookings, contract duration, and gross-margin contribution; absent segment-level disclosure, the financial impact is too diluted to justify a thematic position.
• For REGN, treat data-network access as an R&D productivity watch item, not a catalyst trade. Reassess after trial enrollment timelines or pipeline productivity demonstrate measurable improvement; the thesis is invalidated if added data spend fails to shorten development cycles or improve probability-adjusted pipeline value.